ArticleBosnian journal of basic medical sciences2021
ANKRD22 enhances breast cancer cell malignancy by activating the Wnt/β-catenin pathway via modulating NuSAP1 expression.
Article in Bosnian journal of basic medical sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Genome-Wide Association Analysis and Genomic Prediction of Thyroglobulin Plasma Levels.International journal of molecular sciences · 2022Pooled it
- Downregulation of ANKRD22 promotes ovarian cancer cell proliferation by enhancing the immunosuppressive capacity of M-MDSCs.Cancer immunology, immunotherapy : CII · 2026Article
- ANKRD22 contributes to NF-κB-associated inflammatory responses in alveolar type II epithelial cells during PMFrontiers in immunology · 2026Article
- Downregulation ofTranslational cancer research · 2025Article
- The role and therapeutic value of NUSAP1 in human cancers.Journal of translational medicine · 2025Review
- A Comprehensive Analysis Exploring the Impact of an Immunogenic Cell Death-Related Panel for Ovarian Cancer.Molecular biotechnology · 2025Article
- Identification of potential shared gene signatures between periodontitis and breast cancer by integrating bulk RNA-seq and scRNA-seq data.Scientific reports · 2025Article
- ANKRD22 participates in the proinflammatory activities of macrophages in the colon cancer tumor microenvironment.Cancer immunology, immunotherapy : CII · 2025Article
- Research progress on NUSAP1 and its role in digestive system neoplasms.Frontiers in oncology · 2025Review
- Macrophage M2 polarization induced by ANKRD22 in lung adenocarcinoma facilitates tumor angiogenesis.Central-European journal of immunology · 2025Article
- Tumour heterogeneity and personalized treatment screening based on single-cell transcriptomics.Computational and structural biotechnology journal · 2025Article
- Article
- Integrated bulk and single-cell profiling characterize sphingolipid metabolism in pancreatic cancer.BMC cancer · 2024Article
- METTL14 promotes lipid metabolism reprogramming and sustains nasopharyngeal carcinoma progression via enhancing mClinical and translational medicine · 2024Article
- ANKRD22 aggravates sepsis-induced ARDS and promotes pulmonary M1 macrophage polarization.Journal of translational autoimmunity · 2024Article
- Mucus production, host-microbiome interactions, hormone sensitivity, and innate immune responses modeled in human cervix chips.Nature communications · 2024Article
- NUSAP1 promotes pancreatic ductal adenocarcinoma progression by drives the epithelial-mesenchymal transition and reduces AMPK phosphorylation.BMC cancer · 2024Article
- Immunotherapeutic value of NUSAP1 associated with bladder cancer through a comprehensive analysis of 33 human cancer cases.American journal of cancer research · 2024Article
- Recognition and combination of multiple cell-death features showed good predictive value in lung adenocarcinoma.Heliyon · 2023Article
- ANKRD29, as a new prognostic and immunological biomarker of non-small cell lung cancer, inhibits cell growth and migration by regulating MAPK signaling pathway.Biology direct · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is one of the most prevalent malignancies in women worldwide. Although great advancements have been achieved in the diagnosis and treatment of breast cancer, the prognosis of patients with breast cancer is still poor due to distal recurrence and metastasis after surgery. This study aimed to assess the role of ankyrin repeat domain 22 (ANKRD22) in the progression of breast cancer and investigate the molecular mechanism. Using immunohistochemistry, we demonstrated that the expression level of ANKRD22 in human breast cancer tissues was significantly higher than that in normal breast tissues. ANKRD22 knockdown inhibited the proliferation, invasion, and epithelial-mesenchymal transition (EMT) of breast cancer cells, as confirmed by BrdU, colony formation, transwell, and immunoblot assays. Immunoblot assays further indicated that ANKRD22 regulated the expression of nucleolar and spindle-associated protein 1 (NuSAP1) and then caused the activation of Wnt/β-catenin signaling pathway. Moreover, overexpression of NUSAP1 reversed the inhibitory effects of ANKRD22 knockdown on the proliferation, invasion, and EMT of breast cancer cells. In summary, this study demonstrated that ANKRD22 enhanced breast cancer cell malignancy by activating the Wnt/β-catenin pathway via modulating NuSAP1 expression, which might shed light on new therapeutic approaches for breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.